The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy
Open accessAbstract
Purpose: To determine whether the application of two courses of cisplatin simultaneously with hyperfractionated radiotherapy improves the outcome in locally advanced and/or node-positive nonmetastatic carcinomas of the head and neck, compared with hyperfractionated radiotherapy alone. Patients and Methods: From July 1994 to July 2000, 224 patients with squamous cell carcinomas of the head and neck (excluding nasopharynx and paranasal sinus) were randomly assigned to hyperfractionated radiotherapy (median dose, 74.4 Gy; 1.2 Gy twice daily) or the same radiotherapy combined with two cycles of concomitant cisplatin (20 mg/m 2 on 5 days of weeks 1 and 5). The primary end point was time to any treatment failure; secondary end points were locoregional failure, metastatic relapse, overall survival, and late toxicity. Results: There was no difference in radiotherapy between both treatment arms (74.4 Gy in 44 days). The full cisplatin dose was applied in 93% and 71% of patients during the first and second treatment cycles, respectively. Acute toxicity was similar in both arms. Median time to any treatment failure was not significantly different between treatment arms (19 months for combined treatment and 16 months for radiotherapy only, respectively) and the failure-free rate at 2.5 years was 45% and 33%, respectively. Locoregional control and distant disease–free survival were significantly improved with cisplatin (log-rank test, P = .039 and .011, respectively). The difference in overall survival did not reach significance (log-rank test, P = .147). Late toxicity was comparable in both treatment groups. Conclusion: The therapeutic index of hyperfractionated radiotherapy is improved by concomitant cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Fu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Thames, H. D., Rodney Withers, H., Peters, L. J., & Fletcher, G. H. (1982) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(82)90517-x · Cited by 840
Horiot, J. C., Le Fur, R., N'Guyen, T., Chenal, C., Schraub, S., Alfonsi, S., Gardani, G., Van Den Bogaert, W., Danczak, S., Bolla, M., et al. (1992) · Radiotherapy and Oncology · doi:10.1016/0167-8140(92)90242-m · Cited by 676
Jeremic, B., Shibamoto, Y., Milicic, B., Nikolic, N., Dagovic, A., Aleksandrovic, J., Vaskovic, Z., & Tadic, L. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1458 · Cited by 473
Cited by
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Nguyen-Tan, P. F., Zhang, Q., Ang, K. K., Weber, R. S., Rosenthal, D. I., Soulieres, D., Kim, H., Silverman, C., Raben, A., Galloway, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3925 · Cited by 475
Lacas, B., Carmel, A., Landais, C., Wong, S. J., Licitra, L., Tobias, J. S., Burtness, B., Ghi, M. G., Cohen, E. E. W., Grau, C., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.01.013 · Cited by 389
Self-citationRisk factors for osteoradionecrosis after head and neck radiation: a systematic review
Nabil, S., & Samman, N. (2012) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.tripleo.2011.07.042 · Cited by 277
Metadata
- Authors
- Huguenin, P., Beer, K. T., Allal, A., Rufibach, K., Friedli, C., Davis, J. B., Pestalozzi, B., Schmid, S., Thöni, A., Ozsahin, M., Bernier, J., Töpfer, M., Kann, R., Meier, U. R., Thum, P., Bieri, S., Notter, M., Lombriser, N., & Glanzmann, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-12-01
- Volume
- 22
- Issue
- 23
- Pages
- 4665-4673
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113541736
- Cited by
- 262
- References
- 13
- FWCI
- 16.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. https://app.cochat.ai/papers/10.1200/jco.2004.12.193
- The paper
- Huguenin, P., Beer, K. T., Allal, A., Rufibach, K., Friedli, C., Davis, J. B., Pestalozzi, B., Schmid, S., Thöni, A., Ozsahin, M., Bernier, J., Töpfer, M., Kann, R., Meier, U. R., Thum, P., Bieri, S., Notter, M., Lombriser, N., & Glanzmann, C. (2004). Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.12.193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.